236 related articles for article (PubMed ID: 34643048)
21. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.
Hong P; Liu R; Rai S; Liu J; Zhou Y; Zheng Y; Li J
J Orthop Surg Res; 2023 Feb; 18(1):116. PubMed ID: 36797767
[TBL] [Abstract][Full Text] [Related]
22. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
23. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Langdahl BL; Libanati C; Crittenden DB; Bolognese MA; Brown JP; Daizadeh NS; Dokoupilova E; Engelke K; Finkelstein JS; Genant HK; Goemaere S; Hyldstrup L; Jodar-Gimeno E; Keaveny TM; Kendler D; Lakatos P; Maddox J; Malouf J; Massari FE; Molina JF; Ulla MR; Grauer A
Lancet; 2017 Sep; 390(10102):1585-1594. PubMed ID: 28755782
[TBL] [Abstract][Full Text] [Related]
24. Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
Nealy KL; Harris KB
Ann Pharmacother; 2021 May; 55(5):677-686. PubMed ID: 32862655
[TBL] [Abstract][Full Text] [Related]
25. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.
Genant HK; Engelke K; Bolognese MA; Mautalen C; Brown JP; Recknor C; Goemaere S; Fuerst T; Yang YC; Grauer A; Libanati C
J Bone Miner Res; 2017 Jan; 32(1):181-187. PubMed ID: 27487526
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Miller PD; Adachi JD; Albergaria BH; Cheung AM; Chines AA; Gielen E; Langdahl BL; Miyauchi A; Oates M; Reid IR; Santiago NR; Vanderkelen M; Wang Z; Yu Z
J Bone Miner Res; 2022 Aug; 37(8):1437-1445. PubMed ID: 35466448
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.
Hagino H; Tanaka K; Silverman S; McClung M; Gandra SR; Charokopou M; Adachi K; Johnson B; Stollenwerk B
Osteoporos Int; 2021 Oct; 32(10):2011-2021. PubMed ID: 33772328
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review.
Poutoglidou F; Samoladas E; Raikos N; Kouvelas D
J Clin Densitom; 2022; 25(3):401-415. PubMed ID: 34920938
[TBL] [Abstract][Full Text] [Related]
29. Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials.
Yang C; Le G; Lu C; Wei R; Lan W; Tang J; Zhan X
Medicine (Baltimore); 2020 Feb; 99(7):e19042. PubMed ID: 32049802
[TBL] [Abstract][Full Text] [Related]
30. Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.
Poole KE; Treece GM; Pearson RA; Gee AH; Bolognese MA; Brown JP; Goemaere S; Grauer A; Hanley DA; Mautalen C; Recknor C; Yang YC; Rojeski M; Libanati C; Whitmarsh T
J Bone Miner Res; 2022 Feb; 37(2):256-264. PubMed ID: 34738660
[TBL] [Abstract][Full Text] [Related]
31. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.
Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
Bone; 2022 Sep; 162():116480. PubMed ID: 35787482
[TBL] [Abstract][Full Text] [Related]
32. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
Han SL; Wan SL
Int J Clin Pract; 2012 Feb; 66(2):199-209. PubMed ID: 22257045
[TBL] [Abstract][Full Text] [Related]
33. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
[TBL] [Abstract][Full Text] [Related]
34. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
35. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
[TBL] [Abstract][Full Text] [Related]
36. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
[TBL] [Abstract][Full Text] [Related]
38. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
39. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study.
Baek KH; Chung YS; Koh JM; Kim IJ; Kim KM; Min YK; Park KD; Dinavahi R; Maddox J; Yang W; Kim S; Lee SJ; Cho H; Lim SK
Endocrinol Metab (Seoul); 2021 Feb; 36(1):60-69. PubMed ID: 33677928
[TBL] [Abstract][Full Text] [Related]
40. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
Kashii M; Kamatani T; Nagayama Y; Miyama A; Tsuboi H; Ebina K
Osteoporos Int; 2023 Mar; 34(3):563-572. PubMed ID: 36585509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
